Generic Name and Formulations:
Ropivacaine HCl 2mg/mL, 5mg/mL, 7.5mg/mL, 10mg/mL; soln for epidural inj; preservative-free.
Fresenius Kabi USA
Indications for NAROPIN:
For the production of local or regional anesthesia for surgery (epidural block including cesarean section, major nerve block, local infiltration) and for acute pain management (epidural continuous infusion or intermittent bolus, eg, postop or labor; local infiltration).
See literature. Avoid intravascular or rapid inj of large volumes. Use test dose (3–5mL of short acting local anesthetic soln containing epinephrine) prior to induction of complete block. Individualize. A cumulative dose of up to 770mg administered over 24 hours is well tolerated in adults with post-op pain management. Debilitated: caution with prolonged periods of administration (eg, >70hrs).
Should only be administered by trained medical professionals; have resuscitative equipment available. Unintended IV inj may result in cardiac arrest (esp. in elderly and patients with concomitant heart disease); prolonged resuscitative efforts may be required. Not for emergency situations. Have protocol for malignant hyperthermia management available. Impaired cardiovascular function. Hypotension. Hypovolemia. Heart block. Hepatic disease. Renal impairment. Labor & delivery; monitor fetal heart rate. Pregnancy (Cat.B). Nursing mothers.
Additive toxic effects with other local anesthetics. Additive cardiac effects possible with concomitant Class III antiarrhythmics (eg, amiodarone); consider ECG monitoring. May be potentiated by CYP1A2 inhibitors (eg, fluvoxamine, theophylline, imipramine) and potent CYP3A4 inhibitors (eg, ketoconazole).
Local anesthetic (amide-type).
Hypotension, GI upset, bradycardia, fever, pain, postop complications, anemia, paresthesia, headache, pruritus, back pain.
Polyamp DuoFit Sterile Pak—5; Single-dose vials (5mg/mL)—1, 5; Single-dose infusion bottles (2mg/mL)—1 (100mL, 200mL)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|